OTC
6.51USD
-0.47 (-6.73%)
We have scored 3 news catalysts on Interpace Biosciences, Inc. (IDXG) over the past 12 months. The biggest single-day move next to one of them came Nov 12, 2025, when IDXG closed −10.7%: “Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results”. Coverage across the window leans positive (average ticker sentiment +0.63). Most of the impact sits in institutional appeal and eps growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
36.1M
P/E
—
EPS
—
Beta
0.60
52W range
1.42-12
Day range
1.42–6.51
Open
1.42
Prev close
6.98
Volume
4.2K
Avg volume
1.7K
Dividend
0.00
IPO
1998-05-20
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Interpace Biosciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for IDXG: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
